1 / 13

Commercializing Life Sciences: UK experience

Commercializing Life Sciences: UK experience. John McCulloch PhD Venture Group Advisor MaRS Discovery District. Personal Story. Post-doc at UCL Medical School, London, UK Licensed monoclonal antibodies to US company Negotiation, license and transfer process Impressions

peri
Télécharger la présentation

Commercializing Life Sciences: UK experience

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Commercializing Life Sciences: UK experience John McCulloch PhD Venture Group Advisor MaRS Discovery District

  2. Personal Story • Post-doc at UCL Medical School, London, UK • Licensed monoclonal antibodies to US company • Negotiation, license and transfer process • Impressions • Ease of funding vs. grant system • Calculation of value and royalty rates • Seeing our work make a difference in the outside world • UK academic culture re. commercialization

  3. Out of the lab • Drug Royalty Corporation in 1994 (DRI Capital) • $1.0 billion under management • Life sciences investor – acquires royalties on drugs, diagnostics, etc. • Security = due diligence • Reviewed hundreds of opportunities, many arising from academic labs in the US and UK • Joined MaRS in 2007

  4. MaRS • MaRS is an international convergence centre based in Toronto • Our mission is to create successful global businesses built from Canada’s science and technology • We provide advisory services, entrepreneurship programs, conference space and office/lab facilities • Wide range of tenants at MaRS: startups to Merck • Recently launched MaRS Innovation • Will commercialize innovations from 16 Toronto institutions • Will select most promising inventions and provide funding for patent prosecution and pre-investment development (POP and “de-risking”)

  5. UK Funding for Life Sciences • Government • Medical Research Council • $1.0 billion R&D 2007-8 • 130 patent families • $152 million license revenue in 2007-8 • Private • Wellcome Trust ($23 billion endowment) • Charities • Cancer Research UK • Arthritis Rheumatism Campaign • National Heart Research Fund • Diabetes UK

  6. BTG plc • National Research Development Corporation (1948) • Mission: to commercialize publicly funded research • Fused with National Enterprise Board in 1981 to create the British Technology Group (BTG) • BTG became custodian of many NRDC assets • 1992 – management buyout • 1995 – LSE flotation = BTG plc • Major BTG assets = MRI, BeneFIX, Campath • Initially “de-risked” technologies and licensed out • Evolved to product development focus

  7. Medical Research Council (MRC) • Founded in 1913 • Numerous landmark discoveries: • Influenza virus • Penicillin • DNA • Link between smoking & lung cancer • Monoclonal antibodies • C. elegans genome • 35 MRC institutes across UK

  8. MRC Laboratory for Molecular Biology • Founded in 1947 (Cambridge, UK) • 13 Nobel laureates • Basic molecular biology research led to a wealth of antibody technologies: • Monoclonal antibodies (Milstein & Kohler, 1975) • NRDC did not file patents! • Chimeric antibodies (Neuberger & Rabbits 1984) • Humanized antibodies (Winter 1986) • Human antibodies (Winter 1990s) • Human antibody genome mice (Neuberger 1990s) • Single domain antibodies (Winter & Tomlinson 2000)

  9. Approved Products • Humira (Abbott) • RA, Crohn’s, psoriasis • US$1.54 billion sales • Tysabri (Biogen Idec) • MS • Actemra (Roche/Chugai) • RA • Campath (Genzyme/Bayer) • lymphoma, RA • Vectibix (Amgen) • Colorectal cancer

  10. Company Formation • Celltech • acquired by UCB ($2.25 billion) • Cambridge Antibody Technology • acquired by AstraZeneca ($1.25 billion) • Domantis • acquired by GlaxoSmithKline ($411 million) • Licenses to 37 other companies • MRC-LMB has played a critical role in the development of powerful, selective drugs for autoimmune disease and cancer

  11. Proceeds to MRC • 2000-2006 • Humanized antibodies = $150 million • Human antibodies = $227 million • MRC-sourced antibody products are still growing • Humira is a blockbuster drug • >$1.5 billion sales/year • MRC uses the revenues from antibody technology to support basic research and expand research infrastructure

  12. Lessons • The UK has been extremely successful in life sciences commercialization based on top tier research • If you can’t patent an initial technology, keep innovating! • LMB created five next generation technologies after mABs • Get the technology out in the field as widely as possible via non-exclusive licenses • Reinvest the proceeds in basic research • Main driver of innovation in MRC-LMB case • Importance of angels

  13. John McCulloch PhD 416-673-8127 jmcculloch@marsdd.com

More Related